Tango Therapeutics announces positive data from Phase 1/2 study of vopimetostat

Tango Therapeutics (TNGX) announced positive data from its ongoing Phase 1/2 study of vopimetostat in patients with MTAP-deleted cancers. Efficacy Results Across Study Indications: As of September 1, 2025, 179 patients were enrolled across all histologies, with 154 at active doses. Ninety-four tumor evaluable patients were enrolled more than 6 months prior to the efficacy analysis and included regardless of outcome. Across cancer types: ORR: 27%; DCR: 78%; mPFS: 6.4 months; 37/94 patients remained on treatment as of September 1, 2025. Efficacy Results in Pancreatic Cancer Patients: As of September 1, 2025, 64 patients with pancreatic cancer were enrolled. 39 of these patients received active doses and were enrolled more than 6 months prior to the analysis; in these patients: ORR in 2L pancreatic cancer patients: 25%; ORR for all pancreatic cancer patients: 15%; DCR for all pancreatic cancer patients: 71%; mPFS in 2L patients: 7.2 months; mPFS in 3L+ patients: 4.1 months; Median follow up: 7.8 months.